文献速递类风湿关节炎

抗炎治疗降低类风湿关节炎患者动脉壁炎症

Arterial wall inflammation in rheumatoid arthritis is reduced by anti-inflammatory treatment.
PubMed 文献 · Semin Arthritis Rheum · 2021-03-17

本研究纳入49例早期和已确诊类风湿关节炎(RA)患者,采用18F-FDG-PET/CT评估抗炎治疗6个月前后的动脉壁炎症。结果显示动脉壁SUVmax总体降低4%,颈动脉和股动脉降幅最大,且动脉壁炎症变化与血沉和C反应蛋白变化显著相关,提示抗炎治疗可能对RA患者心血管事件风险有有利影响。

要点

  • 抗炎治疗6个月后RA患者动脉壁FDG摄取总体降低4%,颈动脉和股动脉降幅最大。
  • 早期与已确诊RA患者动脉壁炎症变化无差异。
  • 动脉壁炎症变化与血沉和C反应蛋白变化显著相关。

核心结论

  • 抗炎治疗可降低RA患者动脉壁炎症,且该降低与血清炎症标志物下降相关。

研究设计与样本

  • 前瞻性评估49例早期和已确诊RA患者抗炎治疗6个月前后的动脉壁炎症,使用18F-FDG-PET/CT定量胸主动脉、腹主动脉、颈动脉、髂动脉和股动脉的SUVmax。

主要发现

  • RA患者总体SUVmax随时间降低4%(差值-0.06,95%CI -0.12至-0.01,p=0.02)。
  • 颈动脉SUVmax降低8%(p=0.001),股动脉降低7%(p=0.005)。
  • 早期与已确诊RA患者动脉壁炎症变化无差异(SUVmax差值0.003,95%CI -0.11至0.12,p=0.95)。
  • 动脉壁炎症变化与血沉和C反应蛋白变化显著相关。

关键数值与推荐

  • 早期RA患者(n=26)接受传统合成改善病情抗风湿药联合或不联合糖皮质激素治疗。
  • 已确诊RA患者(n=23)接受阿达木单抗治疗。

临床怎么用

  • 对RA患者进行有效抗炎治疗可能同时改善动脉壁炎症状态,提示其可能有利于降低心血管事件风险。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Rheumatoid arthritis (RA) patients have an increased risk of cardiovascular disease (CVD), partly due to an increased prevalence of cardiovascular risk factors, but also due to chronic systemic inflammation inducing atherosclerotic changes of the arterial wall. The aim of this study was to determine whether anti-inflammatory therapy for the treatment of RA has favorable effects on arterial wall inflammation in RA patients. METHODS: Arterial wall inflammation before and after 6 months of anti-inflammatory treatment was assessed in 49 early and established RA patients using 18F-fluorodeoxyglucose-positron emission tomography with computed tomography (18F-FDG-PET/CT). Arterial 18F-FDG uptake was quantified as maximum standardized uptake value (SUVmax) in the thoracic aorta, abdominal aorta, carotid, iliac and femoral arteries. Early RA patients (n = 26) were treated with conventional synthetic disease modifying anti-rheumatic drugs with or without corticosteroids, whereas established RA patients (n = 23) were treated with adalimumab. RESULTS: In RA patients, overall SUVmax was over time reduced by 4% (difference -0.06, 95%CI -0.12 to -0.01, p = 0.02), with largest reductions in carotid (-8%, p = 0.001) and femoral arteries (-7%, p = 0.005). There was no difference in arterial wall inflammation change between early and established RA patients (SUVmax difference 0.003, 95%CI -0.11 to 0.12, p = 0.95). Change in arterial wall inflammation significantly correlated with change in serological inflammatory markers (erythrocyte sedimentation rate and C-reactive protein). CONCLUSION: Arterial wall inflammation in RA patients is reduced by anti-inflammatory treatment and this reduction correlates with reductions of serological inflammatory markers. These results suggest that anti-inflammatory treatment of RA has favorable effects on the risk of cardiovascular events in RA patients.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Blanken AB, Agca R, van Sijl AM, et al. Arterial wall inflammation in rheumatoid arthritis is reduced by anti-inflammatory treatment. Semin Arthritis Rheum. 2021. PMID: 33770536. doi:10.1016/j.semarthrit.2021.03.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。